Lilly to Acquire POINT Biopharma to Expand Oncology Capabilitiesinto Next-Generation Radioligand Therapies
Eli Lilly and Company and POINT Biopharma
Global, Inc. announced a definitive agreement for Lilly to acquire
POINT, a radiopharmaceutical company with a pipeline of clinical and
preclinical-stage radioligand therapies in development for the treatment of
cancer. Radioligand therapy can enable the precise targeting of cancer by
linking a radioisotope to a targeting molecule that delivers radiation directly
to cancer cells, enabling significant anti-tumor efficacy while limiting the
impact to healthy tissue.
For further information